Arthur Staddon
MD
Associate Professor of Medicine
👥Biography 个人简介
Arthur Staddon has contributed to clinical evaluation of tazemetostat (an EZH2 inhibitor) in SMARCB1-deficient epithelioid sarcoma, a rare and aggressive soft tissue tumor predominantly affecting young adults. His work contributed to the FDA approval of tazemetostat for epithelioid sarcoma based on single-arm basket trial data. He participates in rare sarcoma clinical trials and multi-institutional outcome registries.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Arthur Staddon 的研究动态
Follow Arthur Staddon's research updates
留下邮箱，当我们发布与 Arthur Staddon（Abramson Cancer Center, University of Pennsylvania）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment